Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Angelika B. Riemer Clear advanced filters

  • Vaccination in glioblastomas does lead to the emergence of tumour-antigen-specific T cells but T cell dysfunction, poor tumour infiltration and persistence hinder efficient tumour killing. Here authors identify a T cell receptor in a vaccinated glioblastoma patient that specifically recognizes the glioblastoma stem cell antigen PTPRZ1 and utilise it in T cell receptor-engineered T (TCR-T) cell therapy, resulting in efficient tumour cell killing in vitro and in a mouse model.

    • Yu-Chan Chih
    • Amelie C. Dietsch
    • Lukas Bunse
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-16

  • The control of translation during mitosis has an important role in cancer cell biology. Here the authors report that in mitotically arrested cancer cells, redistribution of ribosomes towards upstream open reading frames results in enhanced presentation of immunogenic peptides on cancer cell surface.

    • Alexander Kowar
    • Jonas P. Becker
    • Fabricio Loayza-Puch
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-15

  • DNA mismatch repair (MMR)-deficient cancers with microsatellite-instability are characterized by a high load of frameshift mutation-derived neoantigens. Here, by mapping the frameshift mutation landscape and predicting the immunogenicity of the resulting peptides, the authors show evidence of immunoediting in MMR-deficient colorectal and endometrial cancers.

    • Alexej Ballhausen
    • Moritz Jakob Przybilla
    • Matthias Kloor
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-13

  • The mutant IDH1 protein, which is expressed in a large fraction of human gliomas, is shown to be immunogenic; mutant-specific immune responses can be detected in patients with IDH1 mutated gliomas and generated in mice and are shown to treat established IDH1 mutant tumours in a syngeneic MHC humanized mouse model in a CD4 T-cell-dependent manner.

    • Theresa Schumacher
    • Lukas Bunse
    • Michael Platten
    Research
    Nature
    Volume: 512, P: 324-327